The DNA Methylome of Cervical Cells Can Predict the Presence of Ovarian Cancer

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Feb 2

PMID 35105887

Authors

James E Barrett

Allison Jones

Iona Evans

Daniel Reisel

Chiara Herzog

Kantaraja Chindera

Mark Kristiansen

Olivia C Leavy

Ranjit Manchanda

Line Bjorge

Michal Zikan

David Cibula

Martin Widschwendter

Affiliations

Soon will be listed here.

Abstract

The vast majority of epithelial ovarian cancer arises from tissues that are embryologically derived from the Müllerian Duct. Here, we demonstrate that a DNA methylation signature in easy-to-access Müllerian Duct-derived cervical cells from women with and without ovarian cancer (i.e. referred to as the Women's risk IDentification for Ovarian Cancer index or WID-OC-index) is capable of identifying women with an ovarian cancer in the absence of tumour DNA with an AUC of 0.76 and women with an endometrial cancer with an AUC of 0.81. This and the observation that the cervical cell WID-OC-index mimics the epigenetic program of those cells at risk of becoming cancerous in BRCA1/2 germline mutation carriers (i.e. mammary epithelium, fallopian tube fimbriae, prostate) further suggest that the epigenetic misprogramming of cervical cells is an indicator for cancer predisposition. This concept has the potential to advance the field of risk-stratified cancer screening and prevention.

Citing Articles

Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.

Hong M, Ding D Diagnostics (Basel). 2025; 15(4).

PMID: 40002556 PMC: 11854769. DOI: 10.3390/diagnostics15040406.

Potential use of DNA methylation in cervical swabs for early ovarian cancer diagnosis.

Biskup E, Lopacinska-Jorgensen J, Hogdall C, Hogdall E J Ovarian Res. 2025; 18(1):29.

PMID: 39955551 PMC: 11830180. DOI: 10.1186/s13048-025-01609-2.

Using parenclitic networks on phaeochromocytoma and paraganglioma tumours provides novel insights on global DNA methylation.

Brempou D, Montibus B, Izatt L, Andoniadou C, Oakey R Sci Rep. 2024; 14(1):29958.

PMID: 39622952 PMC: 11612305. DOI: 10.1038/s41598-024-81486-9.

Technical and biological sources of unreliability of Infinium probes on Illumina methylation microarrays.

Nazarenko T, Vavourakis C, Jones A, Evans I, Schreiberhuber L, Kastner C Clin Epigenetics. 2024; 16(1):131.

PMID: 39289706 PMC: 11409515. DOI: 10.1186/s13148-024-01739-2.

Exploring cross-tissue DNA methylation patterns: blood-brain CpGs as potential neurodegenerative disease biomarkers.

Mendonca V, Soares-Lima S, Moreira M Commun Biol. 2024; 7(1):904.

PMID: 39060467 PMC: 11282059. DOI: 10.1038/s42003-024-06591-x.

References

Phelan C, Kuchenbaecker K, Tyrer J, Kar S, Lawrenson K, Winham S . Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017; 49(5):680-691. PMC: 5612337. DOI: 10.1038/ng.3826. View

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

Margolin G, Petrykowska H, Jameel N, Bell D, Young A, Elnitski L . Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development. J Mol Diagn. 2016; 18(2):283-98. PMC: 4816708. DOI: 10.1016/j.jmoldx.2015.11.004. View

Das S, Forer L, Schonherr S, Sidore C, Locke A, Kwong A . Next-generation genotype imputation service and methods. Nat Genet. 2016; 48(10):1284-1287. PMC: 5157836. DOI: 10.1038/ng.3656. View

Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C . A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet. 2015; 52(7):465-75. PMC: 4501173. DOI: 10.1136/jmedgenet-2015-103077. View

Yang Y, Wu L, Shu X, Lu Y, Shu X, Cai Q . Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Res. 2018; 79(3):505-517. PMC: 6359948. DOI: 10.1158/0008-5472.CAN-18-2726. View

Pidsley R, Zotenko E, Peters T, Lawrence M, Risbridger G, Molloy P . Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016; 17(1):208. PMC: 5055731. DOI: 10.1186/s13059-016-1066-1. View

Bartlett T, Chindera K, McDermott J, Breeze C, Cooke W, Jones A . Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nat Commun. 2016; 7:11620. PMC: 4890182. DOI: 10.1038/ncomms11620. View

Cheng W, Liu J, Yoshida H, Rosen D, Naora H . Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005; 11(5):531-7. DOI: 10.1038/nm1230. View

10.

Buniello A, MacArthur J, Cerezo M, Harris L, Hayhurst J, Malangone C . The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2018; 47(D1):D1005-D1012. PMC: 6323933. DOI: 10.1093/nar/gky1120. View

11.

Trinh B, Long T, Laird P . DNA methylation analysis by MethyLight technology. Methods. 2002; 25(4):456-62. DOI: 10.1006/meth.2001.1268. View

12.

Mellemkjaer L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, Bray F . Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1784-92. DOI: 10.1158/1055-9965.EPI-11-0009. View

13.

Daenekas B, Perez E, Boniolo F, Stefan S, Benfatto S, Sill M . Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice. Bioinformatics. 2024; 40(2). PMC: 10868300. DOI: 10.1093/bioinformatics/btae029. View

14.

Koestler D, Chalise P, Cicek M, Cunningham J, Armasu S, Larson M . Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics. 2014; 7:8. PMC: 3916313. DOI: 10.1186/1755-8794-7-8. View

15.

Zheng S, Webster A, Dong D, Feber A, Graham D, Sullivan R . A novel cell-type deconvolution algorithm reveals substantial contamination by immune cells in saliva, buccal and cervix. Epigenomics. 2018; 10(7):925-940. DOI: 10.2217/epi-2018-0037. View

16.

Hartmann L, Lindor N . The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med. 2016; 374(5):454-68. DOI: 10.1056/NEJMra1503523. View

17.

Kilaru V, Knight A, Katrinli S, Cobb D, Lori A, Gillespie C . Critical evaluation of copy number variant calling methods using DNA methylation. Genet Epidemiol. 2019; 44(2):148-158. PMC: 7028453. DOI: 10.1002/gepi.22269. View

18.

Dubeau L, Drapkin R . Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol. 2013; 24 Suppl 8:viii28-viii35. PMC: 3805308. DOI: 10.1093/annonc/mdt308. View

19.

Winham S, Armasu S, Cicek M, Larson M, Cunningham J, Kalli K . Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol. 2014; 38(5):457-66. PMC: 4071957. DOI: 10.1002/gepi.21815. View

20.

Yang X, Leslie G, Gentry-Maharaj A, Ryan A, Intermaggio M, Lee A . Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. J Med Genet. 2018; 55(8):546-554. PMC: 6073911. DOI: 10.1136/jmedgenet-2018-105313. View